User banner image
User avatar
  • admin

Posts

MUSSO E80 Muse Sees Strong U.S. Sales Following European Breakout and MUSE Design Award Win

NEW YORK, June 14, 2026 (GLOBE NEWSWIRE) — After winning the prestigious MUSE Design Awards in 2025, the MUSSO E80 Muse achieved breakout success in the...

Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor (NEXPOVIO®) Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congress

The combination of selinexor plus ruxolitinib met the first co-primary endpoint demonstrating a statistically significant improvement of spleen volume reduction (SVR35) of 49.8% for the...

Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting

CDX-622 is a novel, bispecific antibody combining mast cell depletion and TSLP inhibition, two independent pathways contributing to multiple I&I diseases CDX-622 targets the soluble...

Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

 Achieved 100% ORR and 83.3% CR rate at dose level 2 following a single infusion in patients with relapsed/refractory B-NHL in an ongoing Phase 1...

KFSH Highlights Human-Centered AI as a Path to Better Care at HLTH Europe 2026

RIYADH, Saudi Arabia, June 14, 2026 (GLOBE NEWSWIRE) — At HLTH Europe 2026 in Amsterdam, taking place from June 15 to 18, King Faisal Specialist...

Changan Group Unveils Its In-house Developed ADAS — SDA Pilot

CHONGQING, China, June 14, 2026 /PRNewswire/ — At the 28th Chongqing International Auto Exhibition, Changan Group showcased its full brand lineup including CHANGAN NEVO, CHANGAN...

TAIWAN DESIGN POWER Debuts at Busan Design Festival, Showcasing Taiwan’s Design Innovation and Creative Value

The “TAIWAN DESIGN POWER” Taiwan Pavilion, showcased at the Busan Design Festival in South Korea, brings together 25 design projects and 20 industry representatives, demonstrating Taiwan’s...

Phase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism

Multi-organ system and quality-of-life benefits sustained through three and a half years  86% response rate for the multi-component endpoint 89% of patients completed the three-and-a-half-year...

Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

Media Release COPENHAGEN, Denmark; June 13, 2026 Results from the Phase 2 EPCORE® DLBCL-3 trial show fixed-duration epcoritamab monotherapy demonstrated early responses in elderly patients...

HeroMD 4-MAX Claims Evaluated: Why Men Searching “Most Effective 4-in-1 Erectile Dysfunction Formula” Are Comparing SURGE, PRIME and The HERO System Explained

Sublingual Compounded Vardenafil, Sildenafil, Tadalafil, and Apomorphine for Prescription ED Treatment: 10-Minute Onset and 36-Hour Active Window Researched Kennewick, WA, June 13, 2026 (GLOBE NEWSWIRE)...